Histogen Inc HSTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HSTO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.35
- Day Range
- $0.35–0.35
- 52-Week Range
- $0.05–1.05
- Bid/Ask
- $0.35 / $0.37
- Market Cap
- $1.50 Mil
- Volume/Avg
- 3,689 / 21,774
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 78.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.60%
Company Profile
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.histogen.com
Valuation
|
Metric
|
HSTO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.28 |
Price/Sales | 78.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HSTO
|
|---|---|
Quick Ratio | 3.39 |
Current Ratio | 4.05 |
Interest Coverage | — |
Quick Ratio
HSTO
Profitability
|
Metric
|
HSTO
|
|---|---|
Return on Assets (Normalized) | −75.17% |
Return on Equity (Normalized) | −99.77% |
Return on Invested Capital (Normalized) | −81.15% |
Return on Assets
HSTO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gybtphsbt | Dwb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yxyswwxzb | Xvssqz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bngpmcnc | Gktwtt | $97.8 Bil | |
MRNA
| Moderna Inc | Tlnhtvc | Vpyp | $41.3 Bil | |
ARGX
| argenx SE ADR | Sphqdjpln | Xmd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kglyywj | Nxtqb | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Frpplrtz | Jccwb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lqwjkjhq | Vtwrdt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wsjnlyng | Tcgrbcw | $12.5 Bil | |
INCY
| Incyte Corp | Bcdsszrph | Mftjdgr | $11.6 Bil |